Genta

Biotech Stock Mailbag: Bio-Hazards

Biotech Stock Mailbag: Bio-Hazards

The Street

News

Pooled Results of Early Endpoints from Phase 3 Trials of Genasense® in Advanced Melanoma Presented at ASCO

Yahoo/BusinessWire

»

Login or register to post comments

News

Allon, Genta programs win FDA fast-track status

Fierce Biotech

»

4 comments

News

Genta starts phase-2 trial of oncology product Tesetaxal

Pharmabiz

»

120 comments

News

Has Genta's Energizer Bunny of Cancer Drugs Finally Run Out of Juice?

BNET Pharma

»

Login or register to post comments

News

Genta Melanoma Drug Study Disappoints

TheStreet.com

»

Login or register to post comments

News

Genta Announces Closing of $10 Million in Two Offerings of Common Stock and Convertible Notes

Yahoo/BusinessWire

Genta

»

Login or register to post comments

News

Hot Biotech Events for Next Week: BioBuzz

TheStreet.com

»

1 comment